The factors driving therapy resistance in diffuse glioma remain poorly understood. To
identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

The evolutionary processes that drive universal therapeutic resistance in adult patients with
diffuse glioma remain unclear 1 , 2 . Here we analysed temporally separated DNA-…

Patient-based cancer models are essential tools for studying tumor biology and for the
assessment of drug responses in a translational context. We report the establishment a large …

Single-cell RNA sequencing has revolutionized our understanding of cellular heterogeneity,
but routine methods require cell lysis and fail to probe the dynamic trajectories responsible …

Intratumour heterogeneity provides tumours with the ability to adapt and acquire treatment
resistance. The development of more effective and personalised treatments for cancers, …

Single-cell RNA sequencing has revolutionised our understanding of cellular heterogeneity,
but whether using isolated cells or more recent spatial transcriptomics approaches, these …

Many traits of cancer progression (eg, development of metastases or resistance to therapy)
are facilitated by tumour evolution: Darwinian selection of subclones with distinct genotypes …

Background Glioblastoma (GBM) brain tumors lacking IDH1 mutations (IDHwt) have the
worst prognosis of all brain neoplasms. Patients receive surgery and chemoradiotherapy but …

Genomic technologies are increasingly used clinically for both diagnosis and guiding cancer
therapy. However, formalin fixation can compromise DNA quality. This study aimed to …

AIMS To collect prospective, real- time data and lived experiences to determine if the chemo-radiotherapy
pre- treatment information materials we provide to our patients need to be …